Status:

WITHDRAWN

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

Lead Sponsor:

Applied Biology, Inc.

Collaborating Sponsors:

Hospital Universitario Ramon y Cajal

Conditions:

SARS-CoV 2

COVID

Eligibility:

MALE

18+ years

Brief Summary

The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess...

Detailed Description

In late 2019, a novel coronavirus, subsequently named SARS-CoV-2 (COVID-19), was first reported in Hubei province in China. Since it was first reported, a worldwide pandemic has ensued affecting more ...

Eligibility Criteria

Inclusion

  • Male over the age of 18
  • First time present at the site
  • Laboratory confirmed SARS-CoV-2 infection
  • Able to give informed consent

Exclusion

  • Unable to give informed consent
  • Diagnosed with an additional respiratory co-infection
  • XXY males

Key Trial Info

Start Date :

May 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04368897

Start Date

May 1 2020

End Date

December 1 2022

Last Update

July 19 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Universitario Ramon y Cajal

Madrid, Spain